SCHEMBL1754330

SCHEMBL1754330

O=C(O)c1ccc(C(C(=O)Nc2ccccc2)C(=O)Nc2ccccc2)nc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 4/20 0.53
P4HTM Q9NXG6 3/20 0.50
ALDH1A1 P00352 3/20 0.49
RAB9A P51151 3/20 0.49
HDAC1 Q13547 2/20 0.49
NPC1 O15118 2/20 0.49
KDM4E B2RXH2 1/20 0.49
LDHA P00338 1/20 0.45
POLB P06746 1/20 0.44
P4HA1 P13674 2/20 0.43
HSP90AA1 P07900 1/20 0.43
GAA P10253 1/20 0.43
ATM Q13315 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC2 Q92769 1/20 0.43
MIF P14174 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1753891 0.86 L3MBTL1 (0.52) ALDH1A1RAB9AHDAC1NPC1KDM4E
SCHEMBL1754331 0.81 HDAC1 (0.68) HDAC1HDAC3HDAC2
SCHEMBL1753888 0.76 HDAC1 (0.73) ALDH1A1RAB9AHDAC1NPC1POLB
SCHEMBL2108145 0.75 HDAC1 (0.58) HDAC1HDAC3HDAC2
SCHEMBL6450288 0.74 ALDH1A1 (0.84) HCAR3P4HTMALDH1A1RAB9ANPC1
SCHEMBL13290277 0.74 P4HA1 (0.52) HCAR3P4HTMALDH1A1LDHAP4HA1
SCHEMBL26784591 0.73 NPC1 (0.65) P4HTMALDH1A1RAB9ANPC1KDM4E
SCHEMBL1018755 0.72 HCAR3 (0.69) HCAR3P4HTMALDH1A1RAB9ANPC1
SCHEMBL1754074 0.72 HDAC1 (0.63) ALDH1A1RAB9AHDAC1NPC1POLB
SCHEMBL30827553 0.71 P4HA1 (0.57) HCAR3P4HTMALDH1A1LDHAP4HA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1896395-B1 MODIFIED MALONATE DERIVATIVES MERCK SHARP & DOHME (US) 2015-07-15 EP disclosed
US-8158825-B2 Modified malonate derivatives MERCK SHARP & DOHME CORP. (US) 2012-04-17 US disclosed
US-8158825-B2 Modified malonate derivatives MERCK SHARP & DOHME CORP. (US) 2012-04-17 US disclosed
US-8158825-B2 Modified malonate derivatives MERCK SHARP & DOHME CORP. (US) 2012-04-17 US disclosed
US-20100160327-A1 Modified Malonate Derivatives MERCK SHARP & DOHME LLC 2010-06-24 US disclosed
US-20100160327-A1 Modified Malonate Derivatives MERCK SHARP & DOHME LLC 2010-06-24 US disclosed
US-20100160327-A1 Modified Malonate Derivatives MERCK SHARP & DOHME LLC 2010-06-24 US disclosed
EP-1896395-A2 MODIFIED MALONATE DERIVATIVES Merck & Co., Inc. (US) 2008-03-12 EP disclosed
WO-2007002248-A2 MODIFIED MALONATE DERIVATIVES MERCK & CO., INC. (US) 2007-01-04 WO disclosed
WO-2007002248-A2 MODIFIED MALONATE DERIVATIVES MERCK & CO., INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160327-A1 Modified Malonate Derivatives ME2, ME3, ME1 HCAR3 948/4885P4HTM 2552/4885ALDH1A1 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.